AN ACT AMENDING THE NORTH CAROLINA PHARMACY PRACTICE ACT TO ALLOW FOR THE SUBSTITUTION OF AN INTERCHANGEABLE BIOLOGICAL PRODUCT.
House committee substitute makes the following changes to the 1st edition.
GS 90-85.28, as amended in the 1st edition, requires in subsection (b2) that a pharmacist or the pharmacist's designee communicate to the prescriber the product name and manufacturer of the specific interchangeable biological product dispensed to a patient.
Amends subsection GS 90-85.28(b2) to clarify that the communication must be done by making an entry into an interoperable electronic medical records system, electronic prescribing technology, or a pharmacy record that can be electronically accessed by the provider. Adds that the communication may also be made via a pharmacy benefit management system.
Adds a new subsection (b4) to GS 90-85.28 to provide that if the state mandates electronic medical records between a pharmacist and a prescriber as described in subsection (b2), then the pharmacist is only required to communicate the biological product dispensed through an electronic medical records system when such a system is in place and the information is accessible by the prescriber.
Provides that GS 90-85.28(b2) and GS 90- 85.28(b4) expire on October 1, 2020.
© 2021 School of Government The University of North Carolina at Chapel Hill
This work is copyrighted and subject to "fair use" as permitted by federal copyright law. No portion of this publication may be reproduced or transmitted in any form or by any means without the express written permission of the publisher. Distribution by third parties is prohibited. Prohibited distribution includes, but is not limited to, posting, e-mailing, faxing, archiving in a public database, installing on intranets or servers, and redistributing via a computer network or in printed form. Unauthorized use or reproduction may result in legal action against the unauthorized user.